厄贝沙坦与开博通治疗糖尿病肾病的临床观察  

Clinical Observation on Treatment of Diabetic Nephropathy with Irbesartan and Captopril

作　　者：刘燚[1] 姜海红[1] 刘海彤[1] 高慧娟[1] 

机构地区：[1]大庆油田总医院内分泌科,黑龙江大庆163001

出　　处：《黑龙江医学》2006年第10期757-758,共2页Heilongjiang Medical Journal

摘　　要：目的探讨厄贝沙坦开博通治疗糖尿病肾病的疗效。方法选择60例2型糖尿病并发肾脏病变患者,随机分为厄贝沙坦治疗组(30例),与开搏通对照组(30例)。两组患者治疗前后监测血压、24h尿蛋白定量、血肌酐、尿素氮、血钾、血糖、血β2-MG、尿β2-MG等,疗程16周。结果两组病人治疗前后血压、24h尿蛋白定量、血β2-MG、尿β2-MG、血肌酐均有明显下降(P<0·05)。结论厄贝沙坦和开博通均有降压及肾脏保护作用,厄贝沙坦的肾脏保护作用优于开博通,而厄贝沙坦同时具有改善胰岛β细胞功能的作用。且厄贝沙坦副作用较小。Objective To discuss the curative effect of diabetic nephropathy treated with irbesartan and captopril. Methods 60 cases of nephropathy combined with diabetes Ⅱ were divided into two groups （irbesartan group and captopril group） randomly 16 weeks as a course. The blood pressure, urine protein of 24 h, creatinie, BUN, potassium, glucose and so on were monitored. Results All the clinical data monitored had decreased in both groups （ P 〈 0.05）. Conclusion The both ＆nags might have decreasing pressure and preventing kidney action. Irbesartan had strong protection on kidney than eatopril and improving pancreas island function with less side effect.

关 键 词：糖尿病肾病 厄贝沙坦 开博通 

分 类 号：R587.2[医药卫生—内分泌]